The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Helicobacter pylori-related Peptic Ulcer Disease

Helicobacter pylori 연관 소화성궤양

  • Seo, Seung In (Division of Gastroenterology, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine) ;
  • Kim, Hak Yang (Division of Gastroenterology, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine)
  • 서승인 (한림대학교 의과대학 강동성심병원 소화기내과) ;
  • 김학양 (한림대학교 의과대학 강동성심병원 소화기내과)
  • Published : 2014.06.01
⟨ Previous Next ⟩

Abstract

Although the worldwide prevalence of Helicobacter pylori (H. pylori) infection has decreased, peptic ulcer disease (PUD) remains prevalent due to increased usage of non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin. In recent years, the prevalence of H. pylori infection in PUD cases and the distribution of PUD have changed in Korea. The incidence of idiopathic H. pylori-negative ulcers has increased, and research is needed to determine the cause of these idiopathic ulcers. The eradication of H. pylori infection decreases PUD recurrence, and plays a crucial role in the treatment of PUD. The H. pylori test-and-treat strategy is beneficial for patients starting NSAIDs and long-term aspirin users with a history of bleeding ulcers. Although the H. pylori eradication rate is declining steadily due to antibiotic resistance, especially to clarithromycin, current guidelines still recommend standard triple therapy, including a proton pump inhibitor, amoxicillin, and clarithromycin, as a first-line therapy. Recently, various treatment regimens, including sequential or concomitant therapies, have been developed in an attempt to overcome the low eradication rate observed with standard triple therapy. The aim of this article is to review recent trends in H. pylori-related PUD, focusing on epidemiology and treatment strategies.

Keywords

References

  1. McColl KE. Clinical practice: helicobacter pylori infection. N Engl J Med 2010;362:1597-1604. https://doi.org/10.1056/NEJMcp1001110
  2. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006;(2):CD003840.
  3. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993;328:308-312. https://doi.org/10.1056/NEJM199302043280503
  4. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001;15:1949-1958. https://doi.org/10.1046/j.1365-2036.2001.01109.x
  5. Miwa H, Sakaki N, Sugano K, et al. Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter 2004;9:9-16. https://doi.org/10.1111/j.1083-4389.2004.00194.x
  6. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Korean J Gastroenterol 2013;62:3-26. https://doi.org/10.4166/kjg.2013.62.1.3
  7. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-664. https://doi.org/10.1136/gutjnl-2012-302084
  8. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009;29:938-946. https://doi.org/10.1111/j.1365-2036.2009.03960.x
  9. Wang AY, Peura DA. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. Gastrointest Endosc Clin N Am 2011;21:613-635. https://doi.org/10.1016/j.giec.2011.07.011
  10. Peleteiro B, Bastos A, Ferro A, Lunet N. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci 2014 Feb 22 [Epub]. DOI:10.1007/s10620-014-3063-0.
  11. Lim SH, Kwon JW, Kim N, et al. Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. BMC Gastroenterol 2013;13:104. https://doi.org/10.1186/1471-230X-13-104
  12. Borody TJ, George LL, Brandl S, et al. Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol 1991;86:1154-1157.
  13. Ciociola AA, McSorley DJ, Turner K, Sykes D, Palmer JB. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999;94:1834-1840. https://doi.org/10.1111/j.1572-0241.1999.01214.x
  14. Jang MK, Kim HY, Cho BD, et al. Prospective Study for the prevalence of Helicobacter pylori infection in patients with gastric ulcer and duodenal ulcer among Korean population. Korean J Med 1997;52:457-465.
  15. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995;9(Suppl 2):59-69.
  16. Tsuji H, Kohli Y, Fukumitsu S, et al. Helicobacter pylori-negative gastric and duodenal ulcers. J Gastroenterol 1999;34:455-460. https://doi.org/10.1007/s005350050296
  17. Jang HJ, Choi MH, Shin WG, et al. Has peptic ulcer disease changed during the past ten years in Korea? a prospective multi-center study. Dig Dis Sci 2008;53:1527-1531. https://doi.org/10.1007/s10620-007-0028-6
  18. Kim JI, Kim SG, Kim N, et al. Changing prevalence of upper gastrointestinal disease in 28 893 Koreans from 1995 to 2005. Eur J Gastroenterol Hepatol 2009;21:787-793. https://doi.org/10.1097/MEG.0b013e32830e285a
  19. Chow DK, Sung JJ. Is the prevalence of idiopathic ulcers really on the increase? Nat Clin Pract Gastroenterol Hepatol 2007;4:176-177. https://doi.org/10.1038/ncpgasthep0769
  20. Sanchez-Delgado J, Gene E, Suarez D, et al. Has Helicobacter pylori prevalence in bleeding peptic ulcer been underestimated? a meta-regression. Am J Gastroenterol 2011;106:398-405. https://doi.org/10.1038/ajg.2011.2
  21. Sostres C, Lanas A. Epidemiology and demographics of upper gastrointestinal bleeding: prevalence, incidence, and mortality. Gastrointest Endosc Clin N Am 2011;21:567-581. https://doi.org/10.1016/j.giec.2011.07.004
  22. Lau JY, Barkun A, Fan DM, Kuipers EJ, Yang YS, Chan FK. Challenges in the management of acute peptic ulcer bleeding. Lancet 2013;381:2033-2043. https://doi.org/10.1016/S0140-6736(13)60596-6
  23. Kim KH, Kim HY, Choi JW, et al. The influence of Nonsteroidal Anti-inflammatory Drugs on clinical outcome in patients with bleeding peptic ulcers. Korean J Gastroenterol 2005;46:373-380.
  24. Papatheodoridis GV, Archimandritis AJ. Role of Helicobacter pylori eradication in aspirin or non-steroidal antiinflammatory drug users. World J Gastroenterol 2005;11:3811-3816. https://doi.org/10.3748/wjg.v11.i25.3811
  25. Ramsay LE, Sanmuganathan PS, Wallis EJ, Jackson PR. Aspirin for primary prevention: treatment policy should be based on all trial evidence, not subgroup analysis. BMJ 2000;321:1472. https://doi.org/10.1136/bmj.321.7274.1472
  26. Chan FK, Ching JY, Suen BY, Tse YK, Wu JC, Sung JJ. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013;144:528-535. https://doi.org/10.1053/j.gastro.2012.12.038
  27. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-973. https://doi.org/10.1056/NEJM200103293441304
  28. De Leest HT, Steen KS, Lems WF, et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter 2007;12:477-485. https://doi.org/10.1111/j.1523-5378.2007.00543.x
  29. Lai KC, Lau CS, Ip WY, et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003;17:799-805. https://doi.org/10.1046/j.1365-2036.2003.01528.x
  30. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-1418. https://doi.org/10.1111/j.1365-2036.2005.02444.x
  31. Cho DK, Park SY, Kee WJ, et al. The trend of eradication rate of Helicobacter pylori infection and clinical factors that affect the eradication of first-line therapy. Korean J Gastroenterol 2010;55:368-375. https://doi.org/10.4166/kjg.2010.55.6.368
  32. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-414.
  33. Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007;45:4006-4010. https://doi.org/10.1128/JCM.00740-07
  34. Na HS, Hong SJ, Yoon HJ, et al. Eradication rate of first-line and second-line therapy for Helicobacter pylori infection, and reinfection rate after successful eradication. Korean J Gastroenterol 2007;50:170-175.
  35. Kim BG, Lee DH, Ye BD, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007;12:31-35. https://doi.org/10.1111/j.1523-5378.2007.00538.x
  36. Kim N, Park SH, Seo GS, et al. Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea. Helicobacter 2008;13:542-549. https://doi.org/10.1111/j.1523-5378.2008.00648.x
  37. Kawakami Y, Akahane T, Yamaguchi M, et al. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000;44:458-461. https://doi.org/10.1128/AAC.44.2.458-461.2000
  38. Klok RM, Postma MJ, van Hout BA, Brouwers JR. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 2003;17:1237-1245. https://doi.org/10.1046/j.1365-2036.2003.01562.x
  39. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:647-654. https://doi.org/10.1046/j.1365-2036.2003.01746.x
  40. Jung YS, Lee SH, Park CS, et al. Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years. Korean J Gastroenterol 2014;63:82-89. https://doi.org/10.4166/kjg.2014.63.2.82
  41. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012;36:414-425. https://doi.org/10.1111/j.1365-2036.2012.05211.x
  42. Hwang TJ, Kim N, Kim HB, et al. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H: pylori in a single center of Korea. J Clin Gastroenterol 2010;44:536-543.
  43. Woo HY, Park DI, Park H, et al. Dual-priming oligonucleotide-based multiplex PCR for the detection of Helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens. Helicobacter 2009;14:22-28. https://doi.org/10.1111/j.1523-5378.2009.00654.x
  44. Lee HJ, Kim JI, Cheung DY, et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis 2013;208:1123-1130. https://doi.org/10.1093/infdis/jit287
  45. Chung JW, Lee JH, Jung HY, et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011;16:289-294. https://doi.org/10.1111/j.1523-5378.2011.00844.x
  46. Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010;15:38-45. https://doi.org/10.1111/j.1523-5378.2009.00735.x
  47. Yoon JH, Baik GH, Kim YS, et al. Comparison of the eradication rate between 1- and 2-week Bismuth-containing quadruple rescue therapies for Helicobacter pylori eradication. Gut liver 2012;6:434-439. https://doi.org/10.5009/gnl.2012.6.4.434
  48. Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 2002;19:67-70. https://doi.org/10.1016/S0924-8579(01)00456-3
  49. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56:1353-1357. https://doi.org/10.1136/gut.2007.125658
  50. Choi HS, Chun HJ, Park SH, et al. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012;18:2377-2382. https://doi.org/10.3748/wjg.v18.i19.2377
  51. Chung JW, Jung YK, Kim YJ, et al. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial. J Gastroenterol Hepatol 2012;27:1675-1680. https://doi.org/10.1111/j.1440-1746.2012.07249.x
  52. Kwon JH, Lee DH, Song BJ, et al. Ten-day sequential therapy as first-line treatment for Helicobacter pylori infection in Korea: a retrospective study. Helicobacter 2010;15:148-153. https://doi.org/10.1111/j.1523-5378.2010.00748.x
  53. Oh HS, Lee DH, Seo JY, et al. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J Gastroenterol Hepatol 2012;27:504-509. https://doi.org/10.1111/j.1440-1746.2011.06922.x
  54. Park HG, Jung MK, Jung JT, et al. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naive patients. Aliment Pharmacol Ther 2012;35:56-65. https://doi.org/10.1111/j.1365-2036.2011.04902.x
  55. Kim YS, Kim SJ, Yoon JH, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011;34:1098-1105. https://doi.org/10.1111/j.1365-2036.2011.04843.x
  56. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-563. https://doi.org/10.7326/0003-4819-146-8-200704170-00006
  57. Zullo A, Perna F, Hassan C, et al. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 2007;25:1429-1434. https://doi.org/10.1111/j.1365-2036.2007.03331.x
  58. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009;14:109-118. https://doi.org/10.1111/j.1523-5378.2009.00671.x
  59. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-1082. https://doi.org/10.1111/j.1365-2036.2004.02248.x
  60. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011;34:604-617. https://doi.org/10.1111/j.1365-2036.2011.04770.x
  61. Kim SY, Lee SW, Hyun JJ, et al. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy. J Clin Gastroenterol 2013;47:21-24. https://doi.org/10.1097/MCG.0b013e3182548ad4
  62. Lim JH, Lee DH, Choi C, et al. Clinical outcomes of twoweek sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter 2013;18:180-186. https://doi.org/10.1111/hel.12034
  63. McNicholl AG, Marin AC, Molina-Infante J, et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014;63:244-249. https://doi.org/10.1136/gutjnl-2013-304820
  64. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-1600. https://doi.org/10.1111/j.1440-1746.2009.05982.x
  65. O'Connor A, Molina-Infante J, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2013. Helicobacter 2013;18(Suppl 1):58-65. https://doi.org/10.1111/hel.12075
  66. Lee JH, Hong SP, Kwon CI, et al. The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006;48:19-24.
  67. Suzuki H, Nishizawa T, Muraoka H, Hibi T. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob Agents Chemother 2009;53:1720-1721. https://doi.org/10.1128/AAC.00049-09
  68. Furuta T, Sugimoto M, Kodaira C, et al. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. J Gastroenterol Hepatol 2014;29:487-493. https://doi.org/10.1111/jgh.12442
  69. Jeong MH, Chung JW, Lee SJ, et al. Comparison of rifabutin and levofloxacin-based third-line rescue therapies for Helicobacter pylori. Korean J Gastroenterol 2012;59:401-406. https://doi.org/10.4166/kjg.2012.59.6.401
  70. Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter 2010;15:206-213. https://doi.org/10.1111/j.1523-5378.2010.00751.x
  71. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010;32:1069-1079. https://doi.org/10.1111/j.1365-2036.2010.04457.x
  72. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013;47:25-32. https://doi.org/10.1097/MCG.0b013e318266f6cf
  73. Nseir W, Diab H, Mahamid M, et al. Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate: a placebo-controlled study. Aliment Pharmacol Ther 2012;36:231-238. https://doi.org/10.1111/j.1365-2036.2012.05161.x
  74. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-1153. https://doi.org/10.1136/gut.2009.192757

Cited by

  1. Helicobacter pylori 감염과 관련된 철결핍성 빈혈 환아 증례보고 vol.30, pp.3, 2016, https://doi.org/10.7778/jpkm.2016.30.3.042
  2. Helicobacter pylori 감염과 관련된 철결핍성 빈혈 환아 증례보고 vol.30, pp.3, 2016, https://doi.org/10.7778/jpkm.2016.30.3.042